For how we live.
A nationwide study of 624,713 first births found quadrivalent HPV vaccination before pregnancy associated with modestly lower odds of preterm birth and growth restriction, strongest among women vaccinated youngest.
In a Canadian cohort of 228 women with HIV, antibody titres matched those of women without HIV and cervical precancer was not recorded — but protection tracked with viral suppression.
Falling cervical cancer rates after HPV vaccination are well known. A 2026 analysis of mortality data goes further: among women vaccinated at 12–13 with ~90% coverage, no deaths were recorded against about 23 expected.
An IARC worldwide incidence analysis puts the infection-attributable share at 12%, led by H pylori and HPV, with eastern Asia carrying the heaviest load and most of the toll preventable.
For the HPV tests now used in primary screening, a self-collected vaginal sample is about as accurate as one a clinician takes — and mailing kits to under-screened women roughly doubles uptake.
HPV drove 71.7% of US oropharyngeal cancers in the most recent period studied, and incidence in men rose 2.7% a year through 2017. Vaccination cuts the oral infections behind them.
The Women's Preventive Services Initiative now endorses patient-collected HPV tests for average-risk women aged 30 to 65. HRSA has adopted the update for no-cost insurance coverage from 2027.
About 1 in 100,000 men in wealthy countries develop it, and roughly half of cases carry HPV. Absent childhood circumcision, phimosis and smoking raise risk; early spread to the groin drives outcomes.
US guidelines now let women aged 30 to 65 screen every five years with an HPV test. One major body would make that the primary test from age 25 — and self-collected samples work about as well.
Two national studies settle the question the trials could not: in England, cancer rates fell 87% among those vaccinated at 12-13; in Sweden, the risk was cut by nearly two-thirds.
Pooling the trials, one- and two-dose HPV schedules produced lower antibody titres than three doses but still cut persistent infection — with the usual caveat about surrogate endpoints.
WHO and UNICEF estimates put DTP3 coverage at 85% for a second year running. Yellow fever protection sits at 53% in at-risk countries and HPV at 33% in girls, both far below target.
The year-end immunization summary reports 88% fewer measles deaths since 2000, malaria vaccine in 24 African countries, and 25 years without wild polio in the Western Pacific.
IARC and WHO put five modules on screening and precancer management online. The 90-70-90 targets they support depend on health workers who can act on a positive test.